Retinal changes and cardiac remodelling in systemic hypertension

Therapeutic Advances in Cardiovascular Disease

Volumn 3, Issue 3, 2009, Pages 205-214

  Cuspidi, Cesare ^a   Negri, Francesca ^a   Giudici, Valentina ^b   Sala, Carla ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Hypertension; Left ventricular hypertrophy; Retinopathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG DOSE TITRATION; ELECTROCARDIOGRAM; ELECTRORETINOGRAPHY; EYE FUNDUS; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; HYPERTENSION RETINOPATHY; MYDRIASIS; OBESITY; PAPILLEDEMA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TARGET ORGAN;

HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; PROGNOSIS; RETINAL DISEASES; RISK FACTORS; VENTRICULAR REMODELING;

EID: 67449146258     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944709103220     Document Type: Review

References (47)

1. Bock, K.D. (1984) Regression of retinal vascular changes by antihypertensive therapy. Hypertension 6: 158-162.
2. Chaturvedi, N., Porta, M., Klein, R., Orchard, T., Fuller, J., Parving, H.H., et al. for the DIRECT Programe Study Group (2008) Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) on retinopathy in type 1 diabetes: randomised, placebo controlled trials. Lancet 372: 1394-1402.
3. Cuspidi, C., Ambrosioni, E., Mancia, G., Pessina, A.C., Trimarco, B., Zanchetti, A., on behalf of the APROS Investigators ( 2002) Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey, J Hypertens 20: 1307-1314.
4. Cuspidi, C., Macca, G., Salerno, M., Michev, I., Fusi, V., Severgnini B. et al. (2001 ) Evaluation of target organ damage in arterial hypertension: which role for qualitative fundoscopic examination? Ital Heart J 2: 702-706.
5. Cuspidi, C., Mancia, G., Ambrosioni, E., Pessina, A., Trimarco, B. and Zanchetti, A. (2004 a) Left ventricular and carotid structure in untreated, uncomplicated essential hypertension: results from the Assessment Prognostic Risk Observational Survey (APROS). J Hum Hypertens 18: 891-896.
6. Cuspidi, C., Meani, S., Valerio, C., Fusi, V., Sala, C. and Zanchetti, A. (2006) Left ventricular hypertrophy and cardiovascular risk stratification impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives. J Hypertens 24: 1671-1677.
7. Cuspidi, C., Meani, S., Salerno, M., Fusi, V., Severgnini, B., Valerio, C. et al. (2004 b) Retinal microvascular changes and target organ damage in untreated essential hypertensives. J Hypertens 22: 2095-2102.
8. Cuspidi, C., Meani, S., Valerio, C., Fusi, V., Catini, E., Sala, C. et al. (2005) Prevalence and correlates of advanced retinopathy in a large selected hypertensive population. The Evaluation of Target Organ Damage in Hypertension (ETODH) study. Blood Press 14: 25-30.
9. Dahlof, B., Stenkula, S. and Hansson, L. (1992) Hypertensive retinal vascular changes: relationship to left ventricular hypertrophy and arteriolar changes before and after treatment. Blood Press 1: 35-44.
10. Dimmit, S.B., West, J.N., Eames, S.M., Gibson, J.M., Gosling, P. and Litler, W.A. (1989) Usefulness of ophthalmoscopy in mild to moderate hypertension. Lancet 1: 1103-1106.
11. Dodson, P.M., Lip, G.Y.H., Eames, S.M., Gibson, J.M. and Beevers, D.G. (1998) Hypertensive retinopathy: a review of existing classification systems and a suggestion for a simplified grading system. J Hum Hypertens 10: 93-98.
12. Enstrom, I., Burtscher, I.M., Eskilsson, J., Holm, K., Holtas, S., Pennert, K. et al. (2000) Organ damage in treated middle-aged hypertensives compared to normtensives: results from a cross-sectional study in general practice. Blood Press 9: 28-33.
13. Frohlich, E.D., Apstein, C., Chobanian, A.V., Devereux, R.B., Dustan, H.P., Dzau, V. et al. (1992) The heart in hypertension. N Engl J Med 327: 998-1008.
14. Ganau, A., Devereux, R.B., Roman, M.J., de Simone, G., Pickering, T.G., Saba, P.S. et al. (1992) Patterns of left ventricular geometry and geometric remodelling in essential hypertension. J Am Coll Cardiol 19: 1550-1558.
15. Grosso, A., Rabbia, F., Fea, A., Grosso, T., Grignolo, F. and Veglio, F. (2006) Comparison between generalized retinal arteriolar narrowing and left ventricular mass in young untreated hypertensive patients. Blood Press 15: 308-312.
16. Ikram, M., Witteman, J.C.M., Vingerling, J.R., Breteler, M.M.B., Hofman, A. and de Jong, P.T.V.M. (2006) Retinal vessel diameters and risk of hypertension. The Rotterdam Study. Hypertension 47: 189-194.
17. Jennings, G.L.R. and McMullen, J.R. (2007) Left ventricular hypertrophy: beyond the image and defining the human cardiac phenotype in hypertension. J Hypertens 25: 941-947.
18. Kawasaki, R., Wang, J.J., Rochtchina, E., Taylor, B., Wong, T.Y., Tominaga, M. et al. (2006) Cardiovascular risk factors and retinal micro-vascular signs in an adult Japanese population: the Funagata Study. Ophthalmology 113: 1378-1384.
19. Keith, N.M., Wagener, H.P. and Barker, N.W. (1939) Some different types of essential hypertension: their course and prognosis. Ann J Med Sci 191: 332-343.
20. Klein, R., Klein, B.E., Moss, S.E. and Wang, Q. (1994) Hypertension and retinopathy, arteriolar narrowing and arteriovenous nicking in a population. Arch Ophthalmol 112: 92-98.
21. Klingbeil, A.U., Schneider, M., Martus, P., Messerli, F.H. and Schmieder, R. (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115: 41-46.
22. Lang, R.M., Bierig, M., Devereux, R.B., Flachskampf, F.A., Foster, E., Pellikka, P.A. et al. (2005) Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440-1463.
23. Leonetti, G. and Cuspidi, C. (1995) Heart and vascular changes in hypertension. J Hypertens 13(Suppl. 2): S29-S34.
24. Levy, D., Garrison, R.J., Savage, D.D., Kannel, W.B. and Castelli, W.P. (1990) Prognostic implications of echocardiographically-determined left ventricular mass in the Framingham Study. N Engl J Med 322: 1561-1566.
25. Mancia, G., Zanchetti, A., Agabiti-Rosei, E., Benemio, G., de Cesaris, R., Fogari, R. et al. (1997) Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 95: 1464-1470.
26. Mancia, G., de Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G. et al. (2007) Guidelines for the management of arterial hypertension. J Hypertens 25: 1105-1187.
27. Mancia, G., Carugo, S., Grassi, G., Lanzarotti, A., Schiavina, R., Cesana, G. et al. (2002) Prevalence of left ventricular hypertrophy in hypertensive patients with and without blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension 39: 744-749.
28. Messerli, F., Williams, B. and Ritz, E. (2007) Essential hypertension. Lancet 370: 591-603.
29. Muxfeldt, E.S., Bloch, K.V., Nogueira, A.R. and Salles, G.F. (2005) True resistant hypertension: is it possible to be recognized in the office. Am J Hypertens 18: 1534-1540.
30. Palatini, P., Penzo, M., Bongiovì, S., Canali, C. and Pessina, A.C. (1991) Role of ophthalmoscopy in the evaluation of the hypertensive patient: a problem revisited. Cardiologia 36: 713-722.
31. Pose-Reino, A., Rodriguez-Fernandez, M., Hayik, B., Goméz-Ulla Irazabal, F., Carrera-Nouche, M.J., González-Barcala, J. et al. (2007) Relation between changes in retinal circulation and other organ damage in hypertension and regression with antihypertensive treatment. Med Clin (Barc) 128: 605-608.
32. Schillaci, G., de Simone, G., Reboldi, G., Porcellati, C., Devereux, R.B. and Verdecchia, P. (2002) Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. J Hypertens 20: 1519-1525.
33. Shigematsu, Y., Hamada, M., Mukai, M., Matsuoka, H., Sumimoto, T. and Hiwada, K. (1995) Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension. J Hypertens 13: 155-160.
34. Sierra, C., de la Sierra, A., Pare, J.C., Gomez-Angelas, E. and Coca, A. (2002) Correlation between silent cerebral matter lesions and left ventricular structure and geometry in essential hypertension. J Am Hypertens 15: 507-512.
35. Sjalie, A.K., Klein, R., Porta, M. Orchard, T., Fuller, J., Parving, H.H., et al. for the DIRECT Programme Study Group (2008) Effect of candesartan on progression and regression (DIRECT-Protect 2) on retinopathy in type 2 diabetes: a randomised, placebo controlled trial, Lancet 372: 1385-1393.
36. Tikellis, G., Arnett, D.K., Skelton, T.N., Taylor, H.W., Klein, R., Couper, D.J. et al. (2008) Retinal arteriolar narrowing and left ventricular hypertrophy in African Americans. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Hypertens 21: 352-359.
37. Vakili, B.A., Okin, P.M. and Devereux, R.B. (2001) Prognostic implications of left ventricular hypertrophy. Am Heart J 141: 334-341.
38. Viazzi, F., Parodi, D., Leoncini, G., Vettoretti, S., Ratto, E., Vaccaro, V. et al. (2004) Optimizing global risk evaluation in primary hypertension: the role of microalbuminuria and cardiovascular ultrasonography. J Hypertens 22: 907-913.
39. Wachtell, K., Olsen, M.H., Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Nieminen, M.S. et al. (2002) Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. J Hypertens 20: 405-412.
40. Wang, J.J., Mitchell, P., Leung, H., Rochtchina, E., Wong, T.Y. and Klein, R. (2003) Hypertensive retinal vessel signs in a general older population. The Blue Mountains Eye Study. Hypertension 2003 42: 534-541.
41. Wong, T.Y., Klein, R., Duncan, B.B., Nieto, F.J., Klein, B.E., Couper, D.J. et al. (2003) Racial differences in the prevalence of hypertensive retinopathy. Hypertension 41: 1086-1091.
42. Wong, T.Y., Duncan, B.B., Golden, S.H., Klein, R., Couper, D.J., Klein, B.E. et al. (2004) Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk in Communities Study. Invest Ophthalmol Vis Sci 45: 2949-2954.
43. Wong, T.Y., Klein, R., Couper, D.J., Cooper, L.S., Shahar, E., Hubbard, L.D. et al. (2001) Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 358: 1134-1140.
44. Wong, T.Y., Klein, R., Sharret, A.R., Duncan, B.B., Couper, D.J., Tielsch, J.M. et al. (2002) Retinal arteriolar narrowing and risk of coronary heart disease in men and women: the Atherosclerosis Risk in Communities Study. J Am Med Assoc 287: 1153-1159.
45. van Hecke, M.V., Dekker, J.M., Nijpels, G., Moll, A.C., van Leiden, H.A., Heine, R.J. et al. (2003) Retinopathy is associated with cardiovascular and all cause mortality in both diabetic and nondiabetic subjects: the Hoorn Study. Diabetes Care 26: 2958.
46. Yu, T., Mitchell, P., Berry, G., Li, W. and Wang, J.J. (1998) Retinopathy in older persons without diabetes and its relationship to hypertension. Arch Ophthalmol 116: 83-89.
47. Zanchetti, A., Bond, M.G., Hennig, M., Mancia, G., Dal Palù, C., et al. (2002) Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106: 2422-2426.